Regulatory Readiness for 3D-Printed Pharmaceuticals in India: Bridging Innovation and Patient Safety

Abstract

Three-dimensional (3D) printing is increasingly being explored in pharmaceutical manufacturing for its ability to produce customized dosage forms, support decentralized production, and enhance the control of drug delivery systems. It enables the production of customized dose forms and the control of intricate drug pharmacokinetics. However, regulations pertaining to 3D-printed medications are still lacking in India. This article assesses India's regulatory preparedness to implement 3D printing in the pharmaceutical industry while ensuring patient safety. It examines important issues such as material validation, product classification, quality control, and point-of-care manufacturing supervision. The study suggests an adaptable, risk-based approach that is in line with current Indian drug legislation, drawing on international regulatory practices. The responsible integration of 3D-printed medications into India's healthcare system will require strengthening regulatory rules, developing institutional capacity, and encouraging stakeholder participation.